Skip to main content

Mixed Urinary Incontinence

Mixed urinary incontinence (MUI) is involuntary urine loss associated with both urgency and exertion, effort, sneezing, or coughing.[1][2] It is not a single clean disease state; it is the coexistence of stress urinary incontinence or male sphincteric leakage with urgency urinary incontinence / OAB. For the reconstructive urologist and urogynecologist, the central question is which component is driving bother, risk, and treatment failure.

MUI matters because operating on the stress component can leave the urgency component untouched, and treating OAB alone can disappoint a patient whose leakage is mostly urethral. Successful care requires explicit phenotyping, shared goals, and staged or combined therapy rather than reflexively treating one label.

Classification​

The useful clinical classification is symptom predominance:[1]

SubtypeDominant complaintUsual first target
Stress-predominant MUILeakage with cough, lifting, exercise, standing, or position change is more frequent or more bothersomePelvic floor muscle training (PFMT); consider anti-incontinence surgery if persistent
Urgency-predominant MUIUrgency, frequency, nocturia, and UUI episodes are more frequent or more bothersomeBladder training, OAB medication, or OAB procedures
Equal-predominance MUIBoth components are similarly bothersome or difficult to separateCombined behavioral therapy; staged escalation based on diary and patient goals

Predominance is not fixed. A patient may begin as urgency-predominant, improve with OAB therapy, and then become most bothered by residual stress leakage; another may have sling surgery and later reveal persistent urgency that was masked by severe SUI.

Epidemiology and Impact​

MUI is common in women with urinary incontinence and becomes more prevalent with age.[3][4] In NHANES 2017-2018, stress UI was the most common subtype, followed by urgency UI and MUI; MUI affected 18.1% of women with UI overall and 31.4% of women aged 60 years or older.[4] National estimates from the Urologic Diseases in America Project similarly show a large population burden of female UI, with mixed symptoms representing a clinically important subset.[5]

MUI often causes greater bother than isolated SUI or isolated UUI because patients must plan around two leak mechanisms: unpredictable urgency and predictable exertional leakage.[1][6] This is why treatment success should be measured by patient-prioritized symptom reduction, not merely by a cough stress test, pad count, or urgency episode count in isolation.

Pathophysiology​

MUI combines urethral failure and bladder storage failure.

Stress component​

  • Urethral hypermobility — loss of vaginal, fascial, and pelvic-floor support prevents pressure transmission to the urethra during exertion
  • Intrinsic sphincter deficiency — poor urethral coaptation; common after prior urethral surgery, radiation, severe obstetric injury, or complex reconstructive history
  • High abdominal pressure states — obesity, chronic cough, constipation, and high-impact exertion amplify the pressure gradient across the urethra

Urgency component​

  • Detrusor overactivity or afferent hypersensitivity during bladder filling
  • Outlet-associated bladder remodeling from obstruction or dysfunctional voiding
  • Neurogenic disinhibition from stroke, Parkinson disease, multiple sclerosis, spinal disease, or dementia syndromes
  • Local bladder / urethral irritants including UTI, stone, foreign body, mesh erosion, radiation cystitis, and painful bladder syndrome

Urodynamic phenotypes often track symptom predominance: stress-predominant MUI is more likely to show lower maximal urethral closure pressure and bladder-neck descent, whereas urgency-predominant MUI is more likely to show DO, lower cystometric capacity, or increased detrusor wall thickness.[7]

Diagnosis and Evaluation​

Initial workup​

The initial evaluation should prove that both components are present and identify which component should be treated first:[1][2][6]

  • History — onset, triggers, urgency warning time, stress triggers, nocturia, pad use, prior pelvic surgery, childbirth history, radiation, neurologic disease, constipation, medications, UTIs
  • Predominance assessment — ask which leakage type is most frequent, most bothersome, and most important to fix
  • Validated questionnaires — ICIQ-UI-SF, UDI-6, IIQ-7, King's Health Questionnaire, OAB-q; use IPSS in men
  • 3-day bladder diary — voided volumes, urgency grade, leakage timing, fluid/caffeine intake, nocturnal urine volume, pad use
  • Urinalysis +/- culture — rule out infection, glycosuria, pyuria, and hematuria
  • Post-void residual — especially before antimuscarinics, botulinum toxin, sling surgery, or outlet surgery
  • Physical examination — pelvic exam in women; prolapse, atrophy/GSM, urethral mobility, pelvic-floor tone, cough stress test; DRE and focused neurologic exam when relevant
  • Pad test — useful when baseline severity or surgical response needs objective quantification

When to use specialized testing​

Urodynamics are not required for every patient with uncomplicated incontinence, but MUI is a common reason to escalate when symptoms are complex, surgery is being planned, or initial treatment fails.[8][9]

TestBest use in MUI
Multichannel urodynamicsDiscordant symptoms/exam, prior failed surgery, elevated PVR, voiding dysfunction, significant prolapse, neurogenic concern, or preoperative planning when the dominant mechanism is unclear
CystoscopyHematuria, recurrent UTI, prior mesh/sling, radiation, suspected foreign body, fistula, stone, stricture, or bladder-neck pathology
Pelvic / perineal ultrasoundSelected centers use it to evaluate bladder-neck mobility, urethral support, and pelvic-floor morphology; it may complement but does not replace clinical phenotyping.[7]

Red flags for referral: hematuria, recurrent UTIs, obstructive symptoms, elevated PVR, suspected fistula, prior continence surgery with pain or voiding dysfunction, significant prolapse, neurologic disease, or refractory symptoms after appropriate conservative therapy.

Management Principles​

Start with goals, not labels​

The 2024 IUGA committee opinion emphasizes individualized management of the SUI and UUI components rather than a one-size sequence.[1] In practice:

  • Treat the most bothersome component first when one component clearly dominates.
  • Use combined behavioral therapy when both components matter.
  • Counsel that treating one component can unmask the other.
  • Reassess after each step with the same diary/questionnaire metrics used at baseline.

First-line: behavioral and pelvic-floor therapy​

PFMT combined with bladder training is the foundational conservative treatment for women with mixed UI. The ACP guideline recommends PFMT plus bladder training as first-line therapy for MUI, and systematic reviews support behavioral therapy as a high-value, low-harm intervention.[10][11][12]

Core elements:

  • PFMT — strengthens periurethral and perivaginal support for the stress component
  • Bladder training — scheduled voiding, progressive intervals, urgency suppression, and delayed voiding for the urgency component
  • Lifestyle modification — weight loss when appropriate, constipation treatment, smoking cessation, exercise, fluid timing, caffeine/alcohol reduction
  • Pelvic-floor physical therapy — especially when pelvic-floor overactivity, poor coordination, or pain coexists
  • Biofeedback or electrical stimulation — adjuncts for patients who cannot isolate pelvic-floor contraction or fail supervised PFMT alone

Pharmacotherapy​

Medications treat the urgency component; they do not correct urethral hypermobility or intrinsic sphincter deficiency.[1][13]

Medication strategyUse
AntimuscarinicsUrgency-predominant MUI or persistent urgency after PFMT/bladder training; avoid or minimize in cognitively vulnerable older adults
β3 agonistsUrgency-predominant MUI, older patients, constipation-prone patients, or antimuscarinic intolerance; monitor blood pressure with mirabegron
Vaginal estrogenPostmenopausal GSM with urinary symptoms or recurrent UTI risk; local therapy only
Systemic estrogenAvoid for UI treatment; systemic estrogen can worsen incontinence

The ACP guideline recommends pharmacologic therapy when bladder training is unsuccessful, with medication choice guided by tolerability, adverse effects, ease of use, and cost.[10]

Surgery for stress-predominant MUI​

Stress-predominant MUI can be treated surgically after conservative therapy and shared decision-making, but counseling must be explicit: surgery addresses the stress component and may not cure urgency.[1][14]

OptionRole
Midurethral slingStandard surgical option for stress-predominant female MUI when objective SUI is present
Autologous fascial sling / Burch colposuspensionMesh-avoidant or specific anatomic/surgical-context options
Bulking agentLower-risk, lower-durability option for selected patients prioritizing minimal invasiveness

The ESTEEM randomized trial tested perioperative behavioral and PFMT plus midurethral sling versus sling alone in women with MUI. Combined therapy produced slightly greater symptom improvement and reduced additional treatment for urinary symptoms at 12 months, supporting a combined approach when operating on stress-predominant MUI.[14]

Advanced therapy for urgency-predominant or refractory MUI​

When the urgency component remains dominant despite behavioral therapy and medication, treat it as refractory OAB/UUI:

Evidence specific to true MUI is thinner than evidence for isolated OAB or isolated SUI, so patient goals and careful reassessment matter.[1][13]

Special Populations​

Older women​

Older women have higher rates of MUI, more polypharmacy, more constipation, and greater cognitive vulnerability to anticholinergic burden.[4][15] Favor low-risk behavioral therapy, β3 agonists when medication is needed and blood pressure permits, constipation treatment, fall-risk reduction, and caregiver-aware timed voiding.

Men​

MUI in men usually means one of three patterns:

  • Post-prostate-treatment incontinence — sphincter deficiency plus detrusor overactivity after radical prostatectomy, radiation, TURP/HoLEP, or bladder-neck stenosis treatment
  • BPH + OAB — outlet obstruction with storage symptoms
  • Neurogenic or frailty-associated UI — urgency, functional leakage, impaired emptying, and mobility/cognition overlap

Before male sling, AUS, outlet surgery, or botulinum toxin, clarify PVR, obstruction, sphincteric leakage, detrusor overactivity, and the patient's ability to operate devices or perform catheterization.[16][17]

Follow-Up and Failure Patterns​

Track:

  • Patient-prioritized component: stress, urgency, or both
  • 3-day diary episodes and voided volumes
  • Pad count / pad weight
  • Cough stress test response when treating SUI
  • PVR and voiding symptoms when using OAB medications, botulinum toxin, or outlet procedures
  • Adverse effects: constipation, dry mouth, cognitive symptoms, retention, UTI

Common failure patterns:

  • Sling cured stress leakage but urgency persists — treat residual OAB; check for obstruction if new urgency/retention develops.
  • OAB medication improved urgency but leakage persists with exertion — reassess objective SUI and discuss stress-directed therapy.
  • Both components persist — revisit diagnosis: fistula, recurrent UTI, obstruction, pain syndrome, neurologic disease, severe prolapse, or poor adherence to behavioral therapy.

See Also​

References​

1. Jha S, Jeppson PC, Dokmeci F, et al. "Management of Mixed Urinary Incontinence: IUGA Committee Opinion." Int Urogynecol J. 2024;35(2):291-301. doi:10.1007/s00192-023-05694-z

2. Haylen BT, de Ridder D, Freeman RM, et al. "An International Urogynecological Association (IUGA) / International Continence Society (ICS) Joint Report on the Terminology for Female Pelvic Floor Dysfunction." Neurourol Urodyn. 2010;29(1):4-20. doi:10.1002/nau.20798

3. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. "Urinary Incontinence in Women: A Review." JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137

4. Abufaraj M, Xu T, Cao C, et al. "Prevalence and Trends in Urinary Incontinence Among Women in the United States, 2005-2018." Am J Obstet Gynecol. 2021;225(2):166.e1-166.e12. doi:10.1016/j.ajog.2021.03.016

5. Lee UJ, Feinstein L, Ward JB, et al. "Prevalence of Urinary Incontinence Among a Nationally Representative Sample of Women, 2005-2016: Findings From the Urologic Diseases in America Project." J Urol. 2021;205(6):1718-1724. doi:10.1097/JU.0000000000001634

6. Sologuren-Garcia G, Linares CL, Flores JR, et al. "Associated Factors and Quality of Life in Women With Urinary Incontinence in Southern Peru, 2023." Front Public Health. 2024;12:1487330. doi:10.3389/fpubh.2024.1487330

7. Hu Y, Lou Y, Liao L, et al. "Comparison of Urodynamics and Perineal Ultrasonography for the Diagnosis of Mixed Urinary Incontinence in Women." J Ultrasound Med. 2018;37(11):2647-2656. doi:10.1002/jum.14626

8. Glazener CMA, Lapitan MCM. "Urodynamic Investigations for Management of Urinary Incontinence in Adults." Cochrane Database Syst Rev. 2002;(3):CD003195. doi:10.1002/14651858.CD003195

9. Rosier PFWM, Kuo HC, De Gennaro M, et al. "International Consultation on Incontinence 2016; Executive Summary: Urodynamic Testing." Neurourol Urodyn. 2019;38(2):545-552. doi:10.1002/nau.23903

10. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline From the American College of Physicians." Ann Intern Med. 2014;161(6):429-440. doi:10.7326/M13-2410

11. Todhunter-Brown A, Hazelton C, Campbell P, et al. "Conservative Interventions for Treating Urinary Incontinence in Women: An Overview of Cochrane Systematic Reviews." Cochrane Database Syst Rev. 2022;9:CD012337. doi:10.1002/14651858.CD012337.pub2

12. Balk EM, Rofeberg VN, Adam GP, et al. "Pharmacologic and Nonpharmacologic Treatments for Urinary Incontinence in Women: A Systematic Review and Network Meta-analysis of Clinical Outcomes." Ann Intern Med. 2019;170(7):465-479. doi:10.7326/M18-3227

13. Game X, Dmochowski R, Robinson D. "Mixed Urinary Incontinence: Are There Effective Treatments?" Neurourol Urodyn. 2023;42(2):401-408. doi:10.1002/nau.25065

14. Sung VW, Borello-France D, Newman DK, et al. "Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial." JAMA. 2019;322(11):1066-1076. doi:10.1001/jama.2019.12467

15. Vesentini G, O'Connor N, Le Berre M, et al. "Interventions for Treating Urinary Incontinence in Older Women: A Network Meta-analysis." Cochrane Database Syst Rev. 2025;11:CD015376. doi:10.1002/14651858.CD015376.pub2

16. Breyer BN, Kim SK, Kirkby E, Marianes A, Vanni AJ, Westney OL. "Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024)." J Urol. 2024;212(4):531-538. doi:10.1097/JU.0000000000004088

17. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985